Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: A phase II trial of the sarah cannon oncology research consortium

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 1, 2010, Pages 44-50

  Hainsworth, John D ^a,b   Flinn, Ian W ^a,b   Spigel, David R ^a,b   Clark, Bobby L ^a   Griner, Paula L ^a   Vazquez, Elizabeth R ^a   Doss, Habib H ^b   Shipley, Dianna ^b   Franco, Luis A ^c   Burris III, Howard A ^a,b   Greco, F Anthony ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c Watson Clinic   (United States)

Author keywords

Community based clinical trial; Cyclophosphamide; Elderly patients; Mitoxantrone; Vincristine

Indexed keywords

ANTIEMETIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; MITOXANTRONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PREDNISOLONE; VAP CYCLO PROTOCOL; VAP-CYCLO PROTOCOL;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTICLE; BONE PAIN; COLON PERFORATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; LARGE CELL LYMPHOMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; CLINICAL TRIAL; MIDDLE AGED; MORTALITY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISOLONE; VINCRISTINE;

EID: 77954051890     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.004     Document Type: Article

References (23)

1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-42. (Pubitemid 34438862)
2. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non- Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329:987-94.
3. Vose JM, Armitage JO, Weisenburger DD, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988; 6:1838-44. (Pubitemid 19089066)
4. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23:4117-26. (Pubitemid 46211317)
5. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24:3121-7. (Pubitemid 46638950)
6. Habermann TM, Hong F, Morrison VA, et al. The cause of death in diffuse large B-cell lymphoma (DLBCL): results from the USA Intergroup study. Ann Oncol 2008; 19(suppl 4):152 (abstract 228).
7. Hainsworth JD, Litchy S, Lamb MR, et al. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non- Hodgkin's lymphoma: phase II trial. Clin Lymphoma 2003; 4:36-42. (Pubitemid 36826875)
8. McMaster ML, Johnson DH, Greer JP, et al. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma. Cancer 1991; 67:1487-92.
9. O'Reilly SE, Connors JM, Howdle S, et al. In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: results of a phase II study of P/DOCE chemotherapy. J Clin Oncol 1993; 11:2250-7. (Pubitemid 23332264)
10. Tirelli U, Zagonel V, Errante D, et al. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non- Hodgkin's lymphoma. J Clin Oncol 1992; 10:228-36.
11. Young WA, Greco FA, Greer JP, et al. Aggressive non-Hodgkin's lymphoma in the elderly: an effective, well-tolerated treatment regimen containing extended schedule etoposide. J Natl Cancer Inst 1994; 86:1346-7. (Pubitemid 24276798)
12. Bastion Y, Blay JY, Divine M, et al. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival-a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol 1997; 15:2945-53. (Pubitemid 27330023)
13. Tirelli U, Errante D, Van Glabbeke M, et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non- Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16:27-34. (Pubitemid 28041575)
14. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108:3295-301. (Pubitemid 44794222)
15. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17:1244.
16. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
17. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7:379-91.
18. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23:5027-33. (Pubitemid 46224009)
19. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. J Clin Oncol 2006; 24:3187-205. (Pubitemid 46638957)
20. Hochster H, Weller E, Gascoyne RD, et al. Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study. J Clin Oncol 2009; 27:1607-14.
21. Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc 1984; 32:269-73. (Pubitemid 14135573)
22. Brice P, Lepage E, Gisselbrecht C, et al. Aggressive non Hodgkin lymphoma in the elderly. A retrospective study of 72 patients with clinical features and treatment. Nouv Rev Fr Hematol 1990; 32:153-7. (Pubitemid 20163247)
23. Dixon D, Neilan B, Jones S, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 1986; 4:295-305. (Pubitemid 16133082)